BioCryst Pharmaceuticals (BCRX) Competitors $7.70 -0.26 (-3.27%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$7.78 +0.09 (+1.10%) As of 09/19/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. RGEN, ALKS, LGND, FOLD, MNKD, CLDX, NVAX, INVA, DVAX, and OPKShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Its Competitors Repligen Alkermes Ligand Pharmaceuticals Amicus Therapeutics MannKind Celldex Therapeutics Novavax Innoviva Dynavax Technologies OPKO Health Repligen (NASDAQ:RGEN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Which has more volatility and risk, RGEN or BCRX? Repligen has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Does the media refer more to RGEN or BCRX? In the previous week, Repligen had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 15 mentions for Repligen and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.73 beat Repligen's score of 0.76 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher valuation & earnings, RGEN or BCRX? Repligen has higher revenue and earnings than BioCryst Pharmaceuticals. Repligen is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepligen$634.44M10.85-$25.51M-$0.25-489.20BioCryst Pharmaceuticals$450.71M3.59-$88.88M-$0.18-42.78 Do analysts rate RGEN or BCRX? Repligen presently has a consensus price target of $166.67, suggesting a potential upside of 36.28%. BioCryst Pharmaceuticals has a consensus price target of $16.70, suggesting a potential upside of 116.88%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repligen 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Is RGEN or BCRX more profitable? Repligen has a net margin of -2.05% compared to BioCryst Pharmaceuticals' net margin of -6.41%. Repligen's return on equity of 4.61% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Repligen-2.05% 4.61% 3.24% BioCryst Pharmaceuticals -6.41%N/A -1.78% Do insiders & institutionals have more ownership in RGEN or BCRX? 97.6% of Repligen shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryRepligen and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.67B$2.58B$5.79B$10.40BDividend YieldN/A55.37%5.63%4.60%P/E Ratio-42.7822.7276.4826.75Price / Sales3.59689.96531.72124.23Price / CashN/A175.2537.9261.55Price / Book-3.355.3513.726.40Net Income-$88.88M$32.95M$3.29B$271.62M7 Day Performance-2.65%0.90%2.66%3.46%1 Month Performance-8.11%5.76%6.02%9.87%1 Year Performance-5.06%-3.43%80.02%28.45% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.2756 of 5 stars$7.70-3.3%$16.70+116.9%-5.5%$1.67B$450.71M-42.78530Positive NewsHigh Trading VolumeRGENRepligen4.8342 of 5 stars$113.74+0.2%$166.67+46.5%-16.1%$6.40B$673.96M-454.941,778ALKSAlkermes4.5829 of 5 stars$26.52-1.7%$41.85+57.8%-2.0%$4.38B$1.51B12.751,800Positive NewsLGNDLigand Pharmaceuticals4.2311 of 5 stars$165.51-0.1%$176.50+6.6%+58.6%$3.24B$187.58M-41.3880News CoveragePositive NewsHigh Trading VolumeFOLDAmicus Therapeutics4.0564 of 5 stars$7.73-3.3%$16.00+107.0%-24.3%$2.38B$571.16M-64.41480News CoverageAnalyst UpgradeMNKDMannKind4.2921 of 5 stars$5.38-3.4%$11.17+107.6%-19.0%$1.65B$301.74M48.91400Analyst ForecastInsider TradeShort Interest ↓High Trading VolumeCLDXCelldex Therapeutics2.168 of 5 stars$24.50+0.2%$46.67+90.5%-40.2%$1.63B$7.02M-8.14150Analyst ForecastNVAXNovavax4.2081 of 5 stars$8.08+1.3%$14.29+76.8%-30.4%$1.31B$1.08B3.541,990INVAInnoviva4.8401 of 5 stars$19.55+0.9%$42.75+118.7%-2.4%$1.23B$358.71M63.07100Positive NewsShort Interest ↓DVAXDynavax Technologies4.3173 of 5 stars$9.36-0.5%$24.33+160.0%-15.7%$1.10B$316.27M-20.35350Positive NewsOPKOPKO Health4.3519 of 5 stars$1.38-1.4%$2.75+99.3%-8.8%$1.10B$664.03M-5.522,997 Related Companies and Tools Related Companies RGEN Competitors ALKS Competitors LGND Competitors FOLD Competitors MNKD Competitors CLDX Competitors NVAX Competitors INVA Competitors DVAX Competitors OPK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
